Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10909068 | Leukemia Research | 2012 | 5 Pages |
Abstract
The PICALM-MLLT10 fusion gene, generated by the t(10;11)(p12-13;q14-21) translocation, is a rare but recurrent event in acute leukemias. In this study, we assessed the characteristics and outcome of 18 PICALM-MLLT10 AML patients. As compared with non PICALM-MLLT10 patients (n = 72), PICALM-MLLT10 AML were characterized by more frequent extramedullary diseases, CD7 expression and higher platelet counts. Three out of four therapy-related PICALM-MLLT10 AMLs had been previously treated for diffuse large B-cell lymphoma. The complete response rate was 71% after intensive chemotherapy. PICALM-MLLT10 patients had a shorter median overall survival than patients with favorable cytogenetics (12 months vs. not reached, p = 0.07) but not significantly different from those of intermediate (26 months, p = 0.32) or unfavorable cytogenetic groups (8 months, p = 0.13). Long term responses were achieved in a subset of patients after allogeneic stem-cell transplantation but also after high-dose cytarabine.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Cecile Borel, Nicole Dastugue, Valérie Cances-Lauwers, Marie-Joelle Mozziconacci, Thomas Prebet, Norbert Vey, Aranud Pigneux, Eric Lippert, Sorin Visanica, Faezeh Legrand, Jean Philippe Rault, Sylvie Taviaux, Christian Bastard, Francine Mugneret,